A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Exenatide (Byetta)

Exenatide lowers blood sugar and promotes weight loss by mimicking the GLP-1 hormone, used in type 2 diabetes.

First FDA approval2014-12-10
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$18.7M in CY2024 Part D spend14K claims · 5K beneficiaries · 329 plans surveyed

Lowest NADAC
$299.50/unit
1 NDCs benchmarked, lowest of all strengths.
Average NADAC
$299.50
Across all dosage forms in distribution.
Highest NADAC
$299.50
Range is tight.
Plans with PA
48 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Exenatide used for?

Exenatide lowers blood sugar and promotes weight loss by mimicking the GLP-1 hormone, used in type 2 diabetes.

Is there a generic for Exenatide?

No. Exenatide is brand-only with no generic equivalents currently in market.

How much does my plan pay for Exenatide?

Across 329 Part D plans, Exenatide averages $299.50/unit (NADAC). Lowest available: $299.50/unit. Highest in distribution: $299.50/unit.

Is Exenatide on the FDA shortage list?

No. Exenatide is not currently on the FDA Drug Shortage Database.

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

GLP-1 Receptor Agonist3 alternatives in D1
01
Dulaglutide
Brand: TRULICITY
$487.63Lowest NADAC
0Generic mfrs
$7.87BCY24 Part D spend
Compare →
02
Liraglutide
Brand: Saxenda
$39.43Lowest NADAC
6Generic mfrs
$383.1MCY24 Part D spend
Compare →
03
Semaglutide
Brand: OZEMPIC
$33.16Lowest NADAC
0Generic mfrs
$24.17BCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file (1 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.